FLUO.ST FluoGuide A/S
Company Analysis
Latest News
FluoGuide Reaffirms 2026 Outlook, Pushes FG001 Cancer Trial Results to 2027
FluoGuide A/S reaffirmed its 2026 financial outlook and confirmed overall progress remains on track. The company adjusted interim milestones for its lead...
FluoGuide's Cancer-Imaging Drug Hits a Milestone, So Why Are Shares Sliding Nearly 10%?
Shares of FluoGuide A/S dropped sharply to $38.10, a 9.3% decline from recent highs, even as the Danish biotech announced its fluorescent imaging agent cleared...
🔴 FLUO.ST is trading 9.3% down today on profit-taking after early-stage Phase 2 trial results
FLUO.ST is trading 9.3% down at $38.10 as investors digest positive but early-stage Phase 2 data for its lead imaging agent, FG001. • The company announced...
FluoGuide Hits Phase 2 Milestone, Identifying Optimal Dose for Cancer Surgery
FluoGuide A/S met the primary endpoint in the initial part of its Phase 2 clinical trial for FG001. The study successfully identified 0.30 mg/kg as the optimal...
🔴 FluoGuide A/S is trading 6.47% down
FLUO.ST is trading at $39.00, down 6.47%.
🟢 FLUO.ST Surges 9% Following Analyst Forecast of 2027 Profitability
FLUO.ST is trading 9% up at $45.40, driven by a recent analyst forecast. • An analyst, as reported on June 28, 2026, revised expectations for Fluoguide A/S,...
🔴 FLUO.ST is trading 6.3% down today amid broader market weakness
FLUO.ST is trading 6.3% down at $40.20 today as the stock experiences an unresolved selloff amid a mixed-to-weaker broader market backdrop. • The stock...
🔴 FLUO.ST is trading 5.3% down today as it reverses its recent rebound
FLUO.ST is trading 5.3% down today at $43.00, reversing its recent mid-June rebound amid a broader risk-off tone in global equities. • The move comes despite...